Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth H Phillips

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Blood Advances|January 8, 2025
Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international studyElizabeth H Phillips, Nicholas Counsell, Tim Illidge, et al.
British Journal of Haematology|November 24, 2018
Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphomaChristopher P Fox, Elizabeth H Phillips, Jeffery Smith, et al.
Bone Marrow Transplantation|March 14, 2019
Author Correction: High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II StudyElizabeth H Phillips, Michelle M Lannon, Andre Lopes, et al.
Bone Marrow Transplantation|August 15, 2018
High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II StudyElizabeth H Phillips, Michelle M Lannon, Andre Lopes, et al.
British Journal of Haematology|December 21, 2022
Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trialsValeria Fiaccadori, Anouk Neven, Catherine Fortpied, et al.
Blood Advances|January 15, 2020
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphomaTim M Illidge, Elizabeth H Phillips, Nicholas Counsell, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 7, 2017
Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL studyElizabeth H Phillips, Stephen Nash, Toyin Adedayo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2019
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID StudySally F Barrington, Elizabeth H Phillips, Nicholas Counsell, et al.
Ejhaem|July 18, 2022
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trialElizabeth H Phillips, Catherine Burton, Amy A Kirkwood, et al.
British Journal of Haematology|September 1, 2017
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive settingToby A Eyre, Elizabeth H Phillips, Kim M Linton, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Blood Advances|January 8, 2025
Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international studyElizabeth H Phillips, Nicholas Counsell, Tim Illidge, et al.
British Journal of Haematology|November 24, 2018
Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphomaChristopher P Fox, Elizabeth H Phillips, Jeffery Smith, et al.
Bone Marrow Transplantation|March 14, 2019
Author Correction: High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II StudyElizabeth H Phillips, Michelle M Lannon, Andre Lopes, et al.
Bone Marrow Transplantation|August 15, 2018
High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II StudyElizabeth H Phillips, Michelle M Lannon, Andre Lopes, et al.
British Journal of Haematology|December 21, 2022
Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trialsValeria Fiaccadori, Anouk Neven, Catherine Fortpied, et al.
Blood Advances|January 15, 2020
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphomaTim M Illidge, Elizabeth H Phillips, Nicholas Counsell, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 7, 2017
Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL studyElizabeth H Phillips, Stephen Nash, Toyin Adedayo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2019
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID StudySally F Barrington, Elizabeth H Phillips, Nicholas Counsell, et al.
Ejhaem|July 18, 2022
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trialElizabeth H Phillips, Catherine Burton, Amy A Kirkwood, et al.
British Journal of Haematology|September 1, 2017
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive settingToby A Eyre, Elizabeth H Phillips, Kim M Linton, et al.
Pageof 3